S119: CEBPA AND TET2 MUTATIONS COOPERATE TO INDUCE AGGRESSIVE AML VIA GATA-2 DOWNREGULATION

S119: CEBPA AND TET2 MUTATIONS COOPERATE TO INDUCE AGGRESSIVE AML VIA GATA-2 DOWNREGULATION

Bibliographic Details
Main Authors:	E. Heyes, A. S. Wilhelmson, A. Wenzel, M. B. Schuster, M. Ali, T. D’Altri, T. Eder, G. Manhart, E. Rzepa, L. Schmidt, M. Meggendorfer, T. Haferlach, G. Volpe, C. Nerlov, J. Frampton, K. Jae Won, F. Grebien, B. Porse
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843368.69924.20

Similar Items

TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression
by: Elizabeth Heyes, et al.
Published: (2023-10-01)

The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia
by: Teresa D'Altri, et al.
Published: (2020-05-01)

P444: IDENTIFICATION OF FUNCTIONAL GENETIC DEPENDENCIES IN CEBPA-MUTATED ACUTE MYELOID LEUKEMIA
by: L. Proietti, et al.
Published: (2022-06-01)

P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS
by: J.-A. Georgi, et al.
Published: (2022-06-01)

Modeling CEBPA Mutant Acute Myeloid Leukemias
by: Nerlov, C
Published: (2013)

Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
by: Annette Fasan, et al.
Published: (2013-01-01)

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA
by: Christian M. Vonk, et al.
Published: (2024-08-01)

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML
by: Francesco Mannelli, et al.
Published: (2025-03-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
by: Sandra Huber, et al.
Published: (2023-08-01)

The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
by: Stacy Cooper, et al.
Published: (2015-01-01)

P411: SF3B1 MUTATIONS IN AML ARE STRONGLY ASSOCIATED WITH MECOM REARRANGEMENTS AND MAY BE INDICATIVE OF AN MDS PRE-PHASE
by: S. Huber, et al.
Published: (2022-06-01)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
by: Alexander Höllein, et al.
Published: (2019-02-01)

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
by: Frank G. Rücker, et al.
Published: (2024-07-01)

Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies
by: Ludovica Proietti, et al.
Published: (2022-12-01)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
by: Claudia Haferlach, et al.
Published: (2023-08-01)

P467: FUNCTIONAL CHARACTERIZATION OF ABERRANT GATA1 PROTEIN COMPLEXES IN NORMAL AND MALIGNANT HUMAN ERYTHROBLASTS
by: S. Tauchmann, et al.
Published: (2022-06-01)

CEBPA Overexpression Enhances β-Cell Proliferation and Survival
by: Peter N. Ellsworth, et al.
Published: (2024-02-01)

Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient
by: Qiang Ma, et al.
Published: (2021-06-01)

Enhancer and Transcription Factor Dynamics during Myeloid Differentiation Reveal an Early Differentiation Block in Cebpa null Progenitors
by: Sachin Pundhir, et al.
Published: (2018-05-01)

Germline CEBPA mutation in familial acute myeloid leukemia
by: Matilde Boada, et al.
Published: (2021-10-01)

In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.
by: Hong Guo, et al.
Published: (2016-01-01)

P1213: ARTIFICIAL INTELLIGENCE TO PREDICT MEDICAL DIAGNOSIS FROM FLOW CYTOMETRIC RAW DATA IN MATURE B-CELL AND T-CELL NEOPLASMS, AML, ALL, MDS AND MULTIPLE MYELOMA
by: Martha-Lena Müller, et al.
Published: (2023-08-01)

Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia
by: Iris H.I.M. Hollink, et al.
Published: (2011-03-01)

Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression
by: Wei Liu, et al.
Published: (2019-12-01)

P119
by: R. Fadeev, et al.
Published: (2015-11-01)

Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation
by: Lisa J. McReynolds, et al.
Published: (2019-01-01)

Impact of secondary‐type mutations in acute myeloid leukemia with CEBPA mutation
by: Davidson Zhao, et al.
Published: (2024-12-01)

Cebpa is required for haematopoietic stem and progenitor cell generation and maintenance in zebrafish
by: Kemin Chen, et al.
Published: (2024-11-01)

Prognostic Nomogram for Acute Myeloid Leukemia Patients With Biallelic CEBPA Mutations
by: Xiaoyu Xu, et al.
Published: (2021-08-01)

HoxA9 binds and represses the Cebpa +8 kb enhancer.
by: Lei Peng, et al.
Published: (2019-01-01)

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
by: Xiying Ren, et al.
Published: (2023-08-01)

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome
by: Kevin M. Bloh, et al.
Published: (2017-06-01)

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
by: Manja Meggendorfer, et al.
Published: (2017-09-01)

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis
by: Johanna Flach, et al.
Published: (2010-03-01)

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA
by: F. G. Ruecker, et al.
Published: (2022-06-01)

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
by: Theodore P. Braun, et al.
Published: (2019-11-01)

Large-Scale Production of 119mTe and 119Sb for Radiopharmaceutical Applications
by: Kevin T. Bennett, et al.
Published: (2019-02-01)

GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription.
by: Nerlov, C, et al.
Published: (2000)

A comprehensive analysis of CEBPA on prognosis and function in uterine corpus endometrial carcinoma
by: Jiaxing Wang, et al.
Published: (2024-10-01)

CEBPA phase separation links transcriptional activity and 3D chromatin hubs
by: Marie Christou-Kent, et al.
Published: (2023-08-01)